Jane Wasman
CIK: 0001352455
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- May 15, 2026RIGL
RIGEL PHARMACEUTICALS INC
Award(A)Direct5.8K shares- - Jan 7, 2026SLS
SELLAS Life Sciences Group, Inc.
Award(A)Direct50K shares- - May 30, 2025SLS
SELLAS Life Sciences Group, Inc.
Purchase(P)Direct20K shares at avg. $1.69$34K - May 23, 2025RIGL
RIGEL PHARMACEUTICALS INC
Award(A)Direct2.5K shares- - Jan 10, 2025SLS
SELLAS Life Sciences Group, Inc.
Award(A)Direct12.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 15, 2026 |  RIGL RIGEL PHARMACEUTICALS INC | Award(A) | 5,750 | - | $0 | Direct |
| Jan 7, 2026 |  SLS SELLAS Life Sciences Group, Inc. | Award(A) | 50,000 | - | $0 | Direct |
| May 30, 2025 | SLS SELLAS Life Sciences Group, Inc. | Purchase(P) | 20,000 | $1.69 | $33,800 | Direct |
| May 23, 2025 | RIGL RIGEL PHARMACEUTICALS INC | Award(A) | 2,500 | - | - | Direct |
| Jan 10, 2025 | SLS SELLAS Life Sciences Group, Inc. | Award(A) | 12,500 | - | $0 | Direct |
1-5 of 5 transactions
About Wasman Jane
Wasman Jane (SEC CIK 0001352455) files insider reports with the SEC as Director of RIGEL PHARMACEUTICALS INC (RIGL) and Director of SELLAS Life Sciences Group, Inc. (SLS).
Signal8 holds 5 ownership filings by Wasman Jane, all Form 4s, filed between Jan 14, 2025 and May 19, 2026. Those filings report 5 transactions, from Jan 10, 2025 to May 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Wasman Jane's filings is in NEW YORK, NY.
Recent filings by Wasman Jane
- May 15, 2026: Grant or award of RIGL shares (Form 4, code A).
- Jan 7, 2026: Grant or award of SLS shares (Form 4, code A).
- May 30, 2025: Open-market purchase of SLS shares (Form 4, code P).
- May 23, 2025: Grant or award of RIGL shares (Form 4, code A).
- Jan 10, 2025: Grant or award of SLS shares (Form 4, code A).
Other insiders filing for RIGEL PHARMACEUTICALS INC (RIGL)
- Schorno Dean L, EVP & Chief Financial Officer
- Santos David A, EVP, Chief Commercial Officer
- RODRIGUEZ RAUL R, CEO, President
- Furey Raymond J., EVP, GC, CCO & Corp Sec
- HANNAH ALISON L., EVP, Chief Medical Officer
- Ali-Jackson Kamil, Director